- Home
- BRY vs CRGX Comparison
BRY vs CRGX Comparison
Compare BRY & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- CRGX
- Stock Information
- Founded
- BRY 1909
- CRGX 2021
- Country
- BRY United States
- CRGX United States
- Employees
- BRY N/A
- CRGX N/A
- Industry
- BRY Oil & Gas Production
- CRGX
- Sector
- BRY Energy
- CRGX
- Exchange
- BRY Nasdaq
- CRGX Nasdaq
- Market Cap
- BRY 186.1M
- CRGX 190.0M
- IPO Year
- BRY N/A
- CRGX 2023
- Fundamental
- Price
- BRY $3.30
- CRGX $4.27
- Analyst Decision
- BRY Buy
- CRGX Hold
- Analyst Count
- BRY 2
- CRGX 7
- Target Price
- BRY $5.00
- CRGX $4.67
- AVG Volume (30 Days)
- BRY 1.3M
- CRGX 663.4K
- Earning Date
- BRY 08-08-2025
- CRGX 08-11-2025
- Dividend Yield
- BRY 3.64%
- CRGX N/A
- EPS Growth
- BRY N/A
- CRGX N/A
- EPS
- BRY N/A
- CRGX N/A
- Revenue
- BRY $753,737,000.00
- CRGX N/A
- Revenue This Year
- BRY N/A
- CRGX $58.18
- Revenue Next Year
- BRY $0.96
- CRGX N/A
- P/E Ratio
- BRY N/A
- CRGX N/A
- Revenue Growth
- BRY N/A
- CRGX N/A
- 52 Week Low
- BRY $2.11
- CRGX $3.00
- 52 Week High
- BRY $7.02
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- BRY 70.73
- CRGX 45.02
- Support Level
- BRY $2.99
- CRGX $4.33
- Resistance Level
- BRY $3.39
- CRGX $4.48
- Average True Range (ATR)
- BRY 0.16
- CRGX 0.19
- MACD
- BRY 0.08
- CRGX -0.02
- Stochastic Oscillator
- BRY 90.91
- CRGX 21.14
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.